These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 25556152)

  • 1. Medical therapies in pituitary adenomas: Current rationale for the use and future perspectives.
    Cuny T; Barlier A; Feelders R; Weryha G; Hofland LJ; Ferone D; Gatto F
    Ann Endocrinol (Paris); 2015 Feb; 76(1):43-58. PubMed ID: 25556152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of pituitary adenomas].
    Mezosi E; Nemes O
    Orv Hetil; 2009 Sep; 150(39):1803-10. PubMed ID: 19758960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical approach to pituitary tumors.
    Neggers SJ; van der Lely AJ
    Handb Clin Neurol; 2014; 124():303-16. PubMed ID: 25248595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Aggressive and resistant-to-treatment pituitary tumors].
    Cuny T; Chanson P
    Ann Endocrinol (Paris); 2013 Oct; 74 Suppl 1():S3-12. PubMed ID: 24356289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosis and treatment of pituitary adenomas.
    Chanson P; Salenave S
    Minerva Endocrinol; 2004 Dec; 29(4):241-75. PubMed ID: 15765032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas.
    Dogansen SC; Yalin GY; Tanrikulu S; Tekin S; Nizam N; Bilgic B; Sencer S; Yarman S
    Pituitary; 2018 Aug; 21(4):347-354. PubMed ID: 29460202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Dopamine Agonists in Pituitary Adenomas.
    Giraldi EA; Ioachimescu AG
    Endocrinol Metab Clin North Am; 2020 Sep; 49(3):453-474. PubMed ID: 32741482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of pituitary tumors: somatostatin.
    Tichomirowa MA; Daly AF; Beckers A
    Endocrine; 2005 Oct; 28(1):93-100. PubMed ID: 16311415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms.
    Pivonello C; Patalano R; Negri M; Pirchio R; Colao A; Pivonello R; Auriemma RS
    Front Endocrinol (Lausanne); 2021; 12():791633. PubMed ID: 35095761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New medical treatments in pituitary adenomas].
    Drutel A; Caron P; Archambeaud F
    Ann Endocrinol (Paris); 2008 Sep; 69 Suppl 1():S16-28. PubMed ID: 18954854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours.
    Colao A; Filippella M; Pivonello R; Di Somma C; Faggiano A; Lombardi G
    Eur J Endocrinol; 2007 Apr; 156 Suppl 1():S57-S63. PubMed ID: 17413190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on the medical management of pituitary adenomas.
    Pickett CA
    Curr Neurol Neurosci Rep; 2005 May; 5(3):178-85. PubMed ID: 15865883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel somatostatin receptor ligand for human ACTH - and GH -secreting pituitary adenomas.
    Regazzo D; Avallone S; MacSweeney CP; Sergeev E; Howe D; Godwood A; Bennett KA; Brown AJH; Barnes M; Occhi G; Barbot M; Faggian D; Tropeano MP; Losa M; Lasio G; Scaroni C; Pecori Giraldi F
    Eur J Endocrinol; 2024 Jan; 190(1):K8-K16. PubMed ID: 38123488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatostatin analogs in the treatment of acromegaly.
    Lamberts SW; Reubi JC; Krenning EP
    Endocrinol Metab Clin North Am; 1992 Sep; 21(3):737-52. PubMed ID: 1355729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases.
    Yamada S; Fukuhara N; Horiguchi K; Yamaguchi-Okada M; Nishioka H; Takeshita A; Takeuchi Y; Ito J; Inoshita N
    J Neurosurg; 2014 Dec; 121(6):1462-73. PubMed ID: 25237847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Future treatment strategies of aggressive pituitary tumors.
    Lamberts SW; Hofland LJ
    Pituitary; 2009; 12(3):261-4. PubMed ID: 19003539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of aggressive growth hormone secreting pituitary adenomas.
    Donoho DA; Bose N; Zada G; Carmichael JD
    Pituitary; 2017 Feb; 20(1):169-178. PubMed ID: 27987061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pituitary Adenomas: What Are the Key Features? What Are the Current Treatments? Where Is the Future Taking Us?
    Solari D; Pivonello R; Caggiano C; Guadagno E; Chiaramonte C; Miccoli G; Cavallo LM; Del Basso De Caro M; Colao A; Cappabianca P
    World Neurosurg; 2019 Jul; 127():695-709. PubMed ID: 31266132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas.
    Saveanu A; Jaquet P; Brue T; Barlier A
    Mol Cell Endocrinol; 2008 May; 286(1-2):206-13. PubMed ID: 18241980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies.
    Raverot G; Jouanneau E; Trouillas J
    Eur J Endocrinol; 2014 Apr; 170(4):R121-32. PubMed ID: 24431196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.